Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

Kurt A. Jaeckle; S. K. Anderson; Erin L. Twohy; Jesse G. Dixon; Caterina Giannini; Robert Jenkins; Merrill J. Egorin; Jann N. Sarkaria; Paul D. Brown; P. J. Flynn; John Schwerkoske; Jan C. Buckner; Evanthia Galanis

doi:10.1007/s11060-019-03201-3

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

Kurt A. Jaeckle
, S. K. Anderson
, Erin L. Twohy
, Jesse G. Dixon
, Caterina Giannini
, Robert Jenkins
, Merrill J. Egorin
, Jann N. Sarkaria
, Paul D. Brown
, P. J. Flynn
, John Schwerkoske
, Jan C. Buckner
, Evanthia Galanis

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

The last author's first name was truncated in the initial online publication. The original article has been corrected.

Original language	English (US)
Pages (from-to)	583
Number of pages	1
Journal	Journal of neuro-oncology
Volume	143
Issue number	3
DOIs	https://doi.org/10.1007/s11060-019-03201-3
State	Published - Jul 1 2019

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/s11060-019-03201-3

Fingerprint

Dive into the research topics of 'Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)'. Together they form a unique fingerprint.

Cite this

Jaeckle, K. A., Anderson, S. K., Twohy, E. L., Dixon, J. G., Giannini, C., Jenkins, R., Egorin, M. J., Sarkaria, J. N., Brown, P. D., Flynn, P. J., Schwerkoske, J., Buckner, J. C., & Galanis, E. (2019). Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z). Journal of neuro-oncology, 143(3), 583. https://doi.org/10.1007/s11060-019-03201-3

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z). / Jaeckle, Kurt A.; Anderson, S. K.; Twohy, Erin L. et al.
In: Journal of neuro-oncology, Vol. 143, No. 3, 01.07.2019, p. 583.

Research output: Contribution to journal › Comment/debate › peer-review

Jaeckle, KA, Anderson, SK, Twohy, EL, Dixon, JG, Giannini, C , Jenkins, R, Egorin, MJ, Sarkaria, JN, Brown, PD, Flynn, PJ, Schwerkoske, J, Buckner, JC & Galanis, E 2019, 'Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)', Journal of neuro-oncology, vol. 143, no. 3, pp. 583. https://doi.org/10.1007/s11060-019-03201-3

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C , Jenkins R et al. Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z). Journal of neuro-oncology. 2019 Jul 1;143(3):583. doi: 10.1007/s11060-019-03201-3

Jaeckle, Kurt A. ; Anderson, S. K. ; Twohy, Erin L. et al. / Correction to : Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z). In: Journal of neuro-oncology. 2019 ; Vol. 143, No. 3. pp. 583.

@article{0adaf13857ae4b32bf4b985e2682fb6f,

title = "Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)",

abstract = "The last author's first name was truncated in the initial online publication. The original article has been corrected.",

author = "Jaeckle, \{Kurt A.\} and Anderson, \{S. K.\} and Twohy, \{Erin L.\} and Dixon, \{Jesse G.\} and Caterina Giannini and Robert Jenkins and Egorin, \{Merrill J.\} and Sarkaria, \{Jann N.\} and Brown, \{Paul D.\} and Flynn, \{P. J.\} and John Schwerkoske and Buckner, \{Jan C.\} and Evanthia Galanis",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = jul,

day = "1",

doi = "10.1007/s11060-019-03201-3",

language = "English (US)",

volume = "143",

pages = "583",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Correction to

T2 - Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

AU - Jaeckle, Kurt A.

AU - Anderson, S. K.

AU - Twohy, Erin L.

AU - Dixon, Jesse G.

AU - Giannini, Caterina

AU - Jenkins, Robert

AU - Egorin, Merrill J.

AU - Sarkaria, Jann N.

AU - Brown, Paul D.

AU - Flynn, P. J.

AU - Schwerkoske, John

AU - Buckner, Jan C.

AU - Galanis, Evanthia

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The last author's first name was truncated in the initial online publication. The original article has been corrected.

AB - The last author's first name was truncated in the initial online publication. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85067028011

UR - https://www.scopus.com/pages/publications/85067028011#tab=citedBy

U2 - 10.1007/s11060-019-03201-3

DO - 10.1007/s11060-019-03201-3

M3 - Comment/debate

C2 - 31165953

AN - SCOPUS:85067028011

SN - 0167-594X

VL - 143

SP - 583

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 3

ER -

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this